Baldwin Wealth Partners’s Pacira BioSciences PCRX Stock Holding History

Baldwin Wealth Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-104	Closed	-$1.56K	–	786
2024 Q3	$1.56K	Hold	104	–	–	﹤0.01%	975
2024 Q2	$2.98K	Hold	104	–	–	﹤0.01%	631
2024 Q1	$3.04K	Hold	104	–	–	﹤0.01%	627
2023 Q4	$3.51K	Hold	104	–	–	﹤0.01%	643
2023 Q3	$3.19K	Hold	104	–	–	﹤0.01%	659
2023 Q2	$4.17K	Hold	104	–	–	﹤0.01%	664
2023 Q1	$4.24K	Hold	104	–	–	﹤0.01%	687
2022 Q4	$4.01K	Buy	+104	New	+$5.06K	﹤0.01%	676

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Baldwin Wealth Partners's PCRX Position: Q4 2024 in Review

Baldwin Wealth Partners sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 104 shares — an estimated $1.56K sold.

Baldwin Wealth Partners first reported a position in PCRX in Q4 2022 and held it in 8 quarters. The position peaked at $4.24K in Q1 2023. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

Baldwin Wealth Partners reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
Baldwin Wealth Partners sold 104 Pacira BioSciences shares in Q4 2024, an estimated $1.56K.
Baldwin Wealth Partners first reported a position in Pacira BioSciences in Q4 2022 and held it in 8 quarters.
Baldwin Wealth Partners's Pacira BioSciences position peaked at $4.24K in Q1 2023.
233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Baldwin Wealth Partners's 13F filing for Q4 2024, filed 22 Jan 2025.